Q: This stock is up 50% in less than a month and is at a 52 week high it also will be making about 270 million going forward this year. They get to keep 90% of that. My simple math has them at a P/E of 6.4 on a forward basis if they don’t overachieve. There drug is getting traction into the hospitals and with the doctors due to its drug profile.
Aurina has another drug in the pipeline going into phase two that looks good and I hope they go after rheumatoid arthritis. To me everything looks good here. This is my fun stock to stop me from becoming too bored and is finally becoming exciting.
What do you folks think is going on here regarding the big move in the stock price and where it could go. Looks like the existing drug revenue tops out an around 600 million annually.
Aurina has another drug in the pipeline going into phase two that looks good and I hope they go after rheumatoid arthritis. To me everything looks good here. This is my fun stock to stop me from becoming too bored and is finally becoming exciting.
What do you folks think is going on here regarding the big move in the stock price and where it could go. Looks like the existing drug revenue tops out an around 600 million annually.
5i Research Answer:
There has been minimal news since AUPH raised its revenue outlook in late July. The stock has seen some good relative strength and momentum and was mentioned in Investors' Business Daily. The recent quarter was solid and we note that EPS estimates have ticked higher in the past four weeks. There has been some (net) insider buying this year and it has also seen some broker upgrades. For a small company momentum can be quite powerful, and there is also likely some short covering (8% short interest). With more than $200M cash and EPS growth of 15%+ going forward, we can see why investors are interested here at 18X earnings.